Experimental drug returns sight to former rugby player
Gene therapy returned sight for Rory Dewar, a former rugby player who lost his eyesight at the age of 22 due to a rare disorder, The Daily Mail reported.
Rory was diagnosed with Leber's hereditary optical neuropathy (LHON), in which healthy cells in the retina die due to a gene mutation, leading to the death of the optic nerve. One out of 30,000 people is affected by this disease, and it is usually either young people between the ages of 15 and 25, or menopausal women. Most patients do not know anything about the disease until their vision begins to deteriorate sharply. There is no cure and volunteers in the Colorado trial had a lab-engineered virus injected into their eyes.
The first results in Rory appeared within 24 hours after the injection. Rory says that he will always be grateful for his fate in participating in these clinical studies that have changed his life for the better.
GenSight Biologics representatives are now negotiating with the U.S. Food and Drug Administration and the European medical agency to get approval for their new medicine called Lumevoq.
Rory hopes that this medicine will be approved and that it will help other people with a serious, yet formally incurable disease.




















Ucom Supports Coca-Cola Fest 2026
“Orran” Students Start the New Academic Year with Support from “The Power of One Dram”
Harutyun Harutyunyan: “The Government Has No Intention of Applying for EU Membership
and Adopted th...
All Armflix Content Is Once Again Available on Uplay
The Unprecedented Educational Summer of the 'Armenian Virtuosos'
Hayk Melikyan Opens the 5th Festival of Armenian Culture in Katowice
Become a Unibank shareholder and acquire perpetual bonds with a 13.25% yield
EBRD’s AMD-denominated bonds listed on AMX; Converse Bank acted as underwriter
Ucom Continues Large-Scale Network Modernization, Expanding 5G Coverage and Enhancing Connectivity